Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fractional-dose PCV10 mass vaccination campaigns in children in Niger
PACTR202112574484846Phase 4Recruiting
- Sponsor
- Illumina
- Start
- Dec 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of pneumococcal conjugate vaccine in pneumococcal disease (3 arms), sponsored by Illumina. Primary endpoints: Reduction in vaccine-type nasopharyngeal pneumococcal carriage and Prevalence of non-vaccine-type pneumococcal colonization. Started Dec 2021; status: recruiting.
02
Drugs
pneumococcal conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on PACTR202112574484846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202112574484846.